Project Grant R41CA302019
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $305K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- The National Cancer Institute awarded a $148,500 Project Grant under the Cancer Biology Research Program (CFDA 93.396) to the University of North Texas to evaluate the role of extracellular vesicles in modulating the tumor microenvironment, with a focus on their impact on T cell infiltration and suppression in non-small cell lung cancer (NSCLC) and prostate cancer. The project aims to identify specific subpopulations of tumor-derived extracellular vesicles, such as TGN46+ vesicles, that...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $276,544 Project Grant to Ioncologi Inc. on September 1, 2025. The grant supports the development of IOI7, an autologous, ex vivo-expanded, immunomodulatory hematopoietic stem cell (HSC) therapy, for the treatment of immune checkpoint inhibitor-resistant glioblastoma. The key objectives are to: (1) optimize HSC expansion using a closed, scalable, and commercially viable production platform; (2) validate HSC...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
- This federal Project Grant award, valued at $641,936 and funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop novel strategies to program tumor-associated neutrophils as antitumor effector cells for the treatment of glioblastoma (GBM), the most aggressive type of brain cancer. The project will leverage synthetic biology, machine learning, and next-generation sequencing to interrogate tumor-associated neutrophils and develop methods to reprogram...
- The National Cancer Institute (NCI) awarded a $522,491 Cooperative Agreement to Virginia Polytechnic Institute & State University (Virginia Tech) under the Cancer Biology Research (CFDA 93.396) program. The funding supports a 5-year research project to understand the role of interstitial fluid flow in glioblastoma, a deadly brain cancer, and leverage this knowledge to develop novel targeted treatment approaches. The key activities include: Leveraging mathematical modeling to map interstitial...
- This $155,695 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research at Southern Utah University (SUU) to develop enhanced glioblastoma therapy using engineered extracellular vesicles. The 4-year project, starting on Sep 5, 2025, aims to: 1) determine the ability of bovine milk-derived extracellular vesicles modified with the PEP-1-PHOR21 targeting peptide to cross the...
- The National Cancer Institute (NCI) awarded Gigamune, Inc. a $400,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop a novel lentiviral vector for enhanced in vivo delivery of T cell receptors for cell therapy to treat Stage IV melanoma. The project aims to address challenges with current autologous T cell therapies, such as high costs and limited manufacturing capacity, by engineering innovative gene delivery methods to potentially increase patient access...
- This Project Grant award for $249,417.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research federal grant program (CFDA 93.395) to support the development of a drug product called MT-125 for the treatment of recurrent high-grade glioblastomas (GBM). Glioblastoma is an aggressive and deadly form of brain cancer with a very poor prognosis. The award will fund preclinical studies and a Phase 0/1B dose escalation clinical trial of MT-125, a dual inhibitor of...
- The National Cancer Institute (NCI) awarded a $306,871 Project Grant to Vivere Oncotherapies, Inc. under the Cancer Treatment Research federal grant program (CFDA 93.395) to advance the development of their OV-151 oncolytic virotherapy product for the treatment of colorectal cancer. The project aims to: 1) characterize the delivery properties of the OV-151 clinical vector to tumors, 2) optimize the therapeutic cargo delivered by the vector, and 3) develop an inducible promoter to enhance...
- This Project Grant award of $163,640 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to develop novel non-viral gene delivery platforms for the treatment of glioblastoma, an aggressive brain cancer. The study aims to investigate the use of brain-penetrating nanoparticles modified to target tumor cells, and to further optimize gene delivery through focused ultrasound treatment. The research is being conducted at the University of Virginia,...